MedCentralFDA Approval of Milsaperidone Widens Door to Severe Mental Disorder Treatment

The FDA approved milsaperidone (Bysanti) on February 20, 2026 as a first-line atypical antipsychotic for acute bipolar I mania and schizophrenia in adults. The approval expands options for the estimated 4 million US adults with schizophrenia spectrum conditions or severe bipolar disorder who face inadequate response or intolerable side effects on existing agents.

⚖️ Professional Impact

• Milsaperidone is the active metabolite of iloperidone, approved via bioequivalence data rather than independent phase 3 trials, a regulatory pathway psychiatrists should understand when discussing evidence with patients
• Orthostatic hypotension requires mandatory titration: 7-day escalation for schizophrenia, 5-day escalation for bipolar mania, making rapid symptom control impossible at initiation
• Boxed warning for dementia-related psychosis mortality applies, requiring careful documentation when considering use in elderly patients with any cognitive impairment
• Phase 3 trial underway as adjunctive MDD treatment, positioning milsaperidone as a potential future option for treatment-resistant depression

🎯 Action Items

• Review current iloperidone patients for potential transition considerations given established bioequivalence
• Counsel patients that titration requirements delay therapeutic onset compared to other atypical antipsychotics
• Screen for orthostatic hypotension risk factors before initiating, particularly in medically complex patients
• Monitor FDA pipeline updates; long-acting injectable formulation is in active development

More in Antipsychotics